Cargando…
Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives
BACKGROUND: A high prevalence of cancers in metabolic disorders, like metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM), recently has been noted, including prostate cancer (PC), which is androgen‐sensitive. However, the pathological relationship among testosterone and insulin and insulin...
Autores principales: | Yanase, Tashihiko, Kawanami, Takako, Tanaka, Tomoko, Tanabe, Makito, Nomiyama, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715889/ https://www.ncbi.nlm.nih.gov/pubmed/29259475 http://dx.doi.org/10.1002/rmb2.12039 |
Ejemplares similares
-
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
por: Tsutsumi, Yoko, et al.
Publicado: (2015) -
Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression
por: Shigeoka, Toru, et al.
Publicado: (2020) -
GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells
por: Takahashi, Hiroyuki, et al.
Publicado: (2019) -
Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line
por: Fukuda, Takashi, et al.
Publicado: (2016) -
Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)